Immunocore Holdings plc
IMCR · XNASCIK 1671927fmd_18MC1HKJ92B20HS7V822QPXJE3Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 23 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | 36 | 174 | 249 | 310 | 400 |
| Cost of revenue | 0 | 1 | 1 | 3 | 5 |
| Gross profit | 36 | 173 | 248 | 307 | 395 |
| Research and development | 100 | 102 | 164 | 222 | 275 |
| Selling, general and administrative | 111 | 123 | 144 | 156 | 165 |
| Operating income | (175) | (52) | (60) | (70) | (45) |
| Interest expense | 6 | 5 | 5 | 19 | 12 |
| Interest and investment income | 0 | 4 | 18 | 26 | 16 |
| Other non-operating income (expense) | (0) | (2) | (1) | 14 | 20 |
| Income before taxes | (180) | (41) | (61) | (53) | (19) |
| Income tax expense | 0 | 12 | (6) | (2) | 16 |
| Net income from continuing operations | (180) | (53) | (55) | (51) | (36) |
| Net income | (180) | (53) | (55) | (51) | (36) |